Jonathan Silverberg
0000-0003-3686-7805
The George Washington University School of Medicine and Health Sciences
11 papers found
Refreshing results…
Mental health interventions for atopic dermatitis: knowledge gaps, pilot programmes and future directions
Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge‐proven food allergy: A systematic review and meta‐analysis
Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets
Pharmacology of orismilast, a potent and selective PDE4 inhibitor
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
Development, Validation, and Interpretation of the PROMIS Itch Questionnaire: A Patient-Reported Outcome Measure for the Quality of Life Impact of Itch
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults
Distribution of atopic dermatitis lesions in United States adults
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
Missing publications? Search for publications with a matching author name.